CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 54 filers reported holding CABALETTA BIO INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $360,227 | +36.4% | 23,668 | +15.7% | 0.00% | – |
| Q2 2023 | $264,190 | +5183.8% | 20,464 | +3132.9% | 0.00% | – |
| Q1 2023 | $5,000 | +83233.3% | 633 | 0.0% | 0.00% | – |
| Q4 2022 | $6 | -99.4% | 633 | -66.8% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 1,909 | +19.5% | 0.00% | – |
| Q2 2022 | $2,000 | -75.0% | 1,598 | -56.9% | 0.00% | – |
| Q1 2022 | $8,000 | -27.3% | 3,708 | +29.7% | 0.00% | – |
| Q4 2021 | $11,000 | -95.0% | 2,859 | -84.3% | 0.00% | – |
| Q3 2021 | $221,000 | +104.6% | 18,205 | +44.5% | 0.00% | – |
| Q2 2021 | $108,000 | -68.1% | 12,602 | -58.7% | 0.00% | – |
| Q1 2021 | $339,000 | +5.0% | 30,497 | +17.6% | 0.00% | – |
| Q4 2020 | $323,000 | +70.9% | 25,922 | +43.0% | 0.00% | – |
| Q3 2020 | $189,000 | +13.2% | 18,128 | +20.6% | 0.00% | – |
| Q2 2020 | $167,000 | +70.4% | 15,035 | +11.7% | 0.00% | – |
| Q1 2020 | $98,000 | +226.7% | 13,461 | +533.5% | 0.00% | – |
| Q4 2019 | $30,000 | – | 2,125 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
| COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
| VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
| Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
| Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
| Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
| TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
| Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |